Hurwitz E, Kashi R, Burowsky D, Arnon R, Haimovich J
Int J Cancer. 1983 Jun 15;31(6):745-8. doi: 10.1002/ijc.2910310612.
Xenogeneic antibodies against the cell-surface IgM of a B-cell lymphoma (38C-13) were coupled through a dextran bridge to the anti-neoplastic drug, daunomycin. The conjugate maintained both its antibody and its drug activity. The effectiveness of the conjugate was tested in vivo in mice challenged with the 38C-13 lymphoma. Drug conjugates of the idiotypic antibodies injected intraperitoneally 2 days after tumor transplantation almost completely inhibited tumor development. The controls, daunomycin-dextran-goat anti-DNP, free daunomycin, or the antibodies alone had no effect or only delayed the tumor development.
针对B细胞淋巴瘤（38C-13）细胞表面IgM的异种抗体通过葡聚糖桥与抗肿瘤药物柔红霉素偶联。该偶联物保留了其抗体和药物活性。在接种了38C-13淋巴瘤的小鼠体内对该偶联物的有效性进行了测试。肿瘤移植后2天腹腔注射独特型抗体的药物偶联物几乎完全抑制了肿瘤的发展。对照组，柔红霉素-葡聚糖-山羊抗DNP、游离柔红霉素或单独的抗体没有效果或只是延缓了肿瘤的发展。
